Trial intelligence / Profile preview

SPH3127 tablets in mild to moderate active ulcerative colitis

CTR20230538Phase 2Completed

Sponsor
Shanghai Pharmaceuticals Holding Co Ltd
Start
Jun 2023
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of sitokiren in autoimmune colitis, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jun 2023; status: completed.

02

Drugs

sitokiren
03

Conditions

autoimmune colitis

Beyond the preview

Go deeper on CTR20230538.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20230538.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call